


Subject: Scope of Practice/Procedure - BLS
Aspirin

Associated Policies: 6006, 6511

- I. Indications
 - A. Chest pain or other signs and symptoms suggestive of acute myocardial infarction (AMI).
- II. Therapeutic Effects
 - A. Appears to impede clotting by blocking prostaglandin synthesis, which prevents formation of the platelet - aggregating substance thromboxane.
- III. Contraindications
 - A. Absolute:
 - 1. Known hypersensitivity to aspirin.
 - B. Relative:
 - 1. None. Benefits of anti-platelet effect strongly outweigh risks of single dose use.
- IV. Adverse Effects
 - A. Hypersensitivity, manifested by anaphylaxis or asthma.
 - B. Nausea.
 - C. Vomiting.
 - D. Gastrointestinal distress.
 - E. Occult bleeding/minor bleeding.
- V. Administration and Dosage
 - A. 324 mg nonenteric-coated (4 (four) chewable 81 mg tablets or 1(one) 325 mg adult tablet), chewed and swallowed.
- VI. Special Information
 - A. Does not increase risk of hemorrhagic stroke.
 - B. Produces a 23% decrease in AMI mortality, even when used without thrombolytic drugs.
 - C. Appears to be safe for use during pregnancy.

Approved: 

Approved as to Form: 

Date: 10/2014